Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
9
Added to
15
Trimmed
6
Exited
3
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $14.70B across 112 positions in their Q3 2019 SEC 13F filing (period ending 2019-09-30). The top 10 positions account for 85.9% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $4.27B | 29.08% | - |
| 2 | INCYIncyte Corporation | $2.37B | 16.15% | +0.0% |
| 3 | ACADACADIA Pharmaceuticals Inc. | $1.47B | 10.00% | +4.0% |
| 4 | ONCBeiGene, Ltd. | $1.44B | 9.81% | - |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $808.79M | 5.50% | - |
| 6 | Amarin Corporation plc | $629.81M | 4.28% | - |
| 7 | GHDXGenomic Health, Inc. | $626.97M | 4.27% | -0.2% |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $511.52M | 3.48% | - |
| 9 | ASNDUSDAscendis Pharma A/S | $326.55M | 2.22% | - |
| 10 | NVTA1EURInvitae Corporation | $169.44M | 1.15% | +125.3% |
| Stock | Value | Shares |
|---|---|---|
| 1K0IGM Biosciences, Inc. | $55.81M | 3,144,000 |
| Neoleukin Therapeutics, Inc. | $32.22M | 11,305,679 |
| ALLKGUSDAllakos Inc. | $26.71M | 339,690 |
| URGNUroGen Pharma Ltd. | $17.82M | 747,751 |
| IFRXInflarx N.V. | $4.39M | 1,778,415 |
| MIRMMirum Pharmaceuticals, Inc. | $3.35M | 333,333 |
| MTNBEURMatinas BioPharma Holdings, Inc. | $1.25M | 1,984,965 |
| LPTXEURLeap Therapeutics, Inc. | $1.15M | 978,454 |
| NEOTEUREvofem Biosciences, Inc. | $514.00K | 102,048 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.